AI-assisted pre-treatment peer review to boost prostate cancer radiation safety

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial evaluates an AI/ML decision-support system used during pre-treatment peer review of prostate cancer radiation therapy plans. It focuses on highlighting provider-variability and optimal cues to help reviewers spot potential planning mistakes early. The approach aims to reduce errors associated with modern, complex techniques like IMRT, VMAT, and IGRT and promote consistent safety standards across diverse clinics. The study involves providers who participate in peer-review sessions at participating sites. Patient-level interventions are not delivered; instead, the workflow is enhanced through AI-assisted review of treatment plans.

Why it matters

Who can join: the full rules

In order to participate in this study a subject must meet all of the eligibility criteria outlined below.

Inclusion Criteria:

Providers only

* ≥18 years
* Peer-review attendees at participating clinics

Patients only

* ≥18 years
* All patients with prostate cancer radiation therapy cases treated at participating sites (no intervention delivered to patients)

Exclusion Criteria:

Providers only

• Providers unwilling/unable to comply with study procedures; sites unable to implement the workflow or provide required outcomes.

Patients and Providers

• Has dementia, altered mental status, or any psychiatric or co-morbid condition prohibiting the understanding or rendering of informed consent

Where it's running

• University of North Carolina at Chapel Hill, Department of Radiation Oncology
  Chapel Hill, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Lukasz Mazur, PhD — UNC Lineberger Comprehensive Cancer Center
• Study coordinator: Olivia Morton
• Email: olivia_roberts@med.unc.edu
• Phone: (984) 974-8441

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.